Method for constructing PD-1 gene modified humanized animal model and use thereof
Provided is a method for preparing a PD-1 gene-modified humanized animal model. The method utilizes the CRIPSR/Cas9 technique to replace partial fragments of a mouse PD-1 gene with fragments of a human PD-1 gene using homologous recombination by constructing a targeting vector, thereby preparing a gene-modified humanized mouse. This mouse can normally express a PD-1 protein containing the functional domain of the human PD-1 protein, and can be used as an animal model for mechanism research regarding PD-1, PD-L1 and other signals, for screening regulators, and for toxicological research. The method has an important and high application value in studies on functions of the PD-1 gene and in the development of new drugs.
1. A humanized mouse whose genome comprises a humanized programmed cell death protein 1 (PD1) gene comprising endogenous exons 1, 3, 4 and 5 and a partially humanized exon 2, wherein the humanized PD1 gene comprises the nucleic acid sequence of SEQ ID NO: 14, and wherein the mouse functionally expresses a humanized PD1.
2. The mouse of claim 1 , wherein the mouse has a C57BL/6 background.
3. A DNA sequence of a humanized mouse PD-1 gene, wherein the DNA sequence encodes SEQ ID NO: 17.
4. A method for preparing a humanized mouse, the method comprising:
(1) providing a plasmid comprising a human PD-1 gene fragment that comprises a nucleic acid sequence that comprises the nucleic acid sequence of SEQ ID NO: 21 flanked by a 5′ homology arm and a 3′ homology arm, wherein the 5′ and 3′ homology arms target exon 2 of a mouse PD-1 gene;
(2) providing two guide RNAs (sgRNAs) that target exon 2 of a mouse PD-1 gene, wherein the two sgRNAs target one sequence selected from the group consisting of SEQ ID NOs: 1-4 and one sequence selected from the group consisting of SEQ ID NOs: 5-8;
(3) modifying the genome of a mouse fertilized egg by using the plasmid of step (1), the sgRNAs of step (2), and Cas9;
(4) transplanting the fertilized egg obtained in step (3) into a female mouse such that a humanized mouse whose genome comprises a humanized PD1 gene is obtained, wherein the humanized PD1 gene comprises SEQ ID NO: 14.
5. The method of claim 4 , wherein the 5′ homology arm has the nucleic acid sequence of SEQ ID NO:18, and the 3′ homology arm has the nucleic acid sequence of SEQ ID NO: 24.
6. A cell or tissue isolated from the mouse of claim 1 .
7. The mouse of claim 1 , wherein the genome of the mouse further comprises a humanized CTLA-4 gene.
8. A method for evaluating effectiveness of a drug, comprising administering the drug to the mouse of claim 1 , wherein the mouse has a tumor expressing human PD-L1; and
determining inhibitory effects of the drug on the tumor.
9. The method of claim 8 , wherein the mouse further comprises a humanized CTLA-4 gene.
10. The method of claim 8 , wherein the drug targets PD-1/PD-L1 pathway.
11. The method of claim 8 , wherein the drug is an anti-human PD-1 antibody.
12. The method of claim 4 , wherein the sgRNAs target SEQ ID NO: 3 and SEQ ID NO: 8.
13. The mouse of claim 1 , wherein exon 2 at the endogenous PD-1 gene locus is modified by CRISPR with sgRNAs that target SEQ ID NO: 3 and SEQ ID NO: 8.
14. A genetically modified mouse or a progeny thereof, wherein the genetically modified mouse is made by the method of claim 4 .
15. The genetically modified mouse of claim 14 , wherein the mouse has a C57BL/6 background.